Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEaRL-X
2025-521196-32-00Phase 3Authorised
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin sodium in venous malformation (VM) and lymphangioma (2 arms), sponsored by Fundació Sant Joan de Déu. Primary endpoints: Localized intravascular coagulopathy and endothelial damage values with/without prophylactic enoxaparin and Hemorrhagic clinical signs related to treatment. Planned start Jul 2025; status: authorised.
02
Drugs
enoxaparin sodium
03
Conditions
venous malformation (VM)lymphangioma
Beyond the preview
Go deeper on 2025-521196-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521196-32-00.